Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts
Executive Summary
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
You may also be interested in...
Genmab Confident It Has Edge Over Roche In Bispecific Battle
Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.
ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics
Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.
Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.